Is it right to buy Galera shares after it surged more than double yesterday?

Who is GRTX? $Galera Therapeutics, Inc.(GRTX)$

Galera Therapeutics, Inc. (Nasdaq: GRTX) is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.

What happened to GRTX?

Galera Therapeutics Inc has announced corrected results from its Phase 3 ROMAN trial of avasopasem for RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC).The corrected data showed that avasopasem achieved statistical significance on the primary endpoint of reduction in the incidence of SOM.Previously it announced that the trial did not achieve statistical significance on the primary endpoint.An error was identified in the statistical program upon further analysis, resulting in improved p-values.16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) vs. placebo group (64%) (p=0.0451) (previously p=0.113) (primary endpoint).56% relative reduction in the number of days of SOM in the avasopasem treatment group (8 days) vs. placebo group (18 days) (p=0.0022) (previously p=0.011) (secondary endpoint).27% relative reduction in the severity of SOM in the avasopasem treatment group (24%) vs. placebo group (33%) (p=0.052) (previously p=0.167).The Company also announced topline results from its single-arm Phase 2a EUSOM trial of avasopasem in Europe.Avasopasem appeared to be generally well tolerated. In EUSOM, the incidence of SOM was 54.5%, and the median number of days of SOM was 9 days, in line with the ROMAN trial.

Then the price of the share surged more than double on this Tuesday.

What we should do?

Let's see some data of the share:

-Traded at $12 back in March.

-Dropped to $1.20 in Oct on false p3 data.

-Sitting at $3 now with positive p3 data.

-280 million shares traded.-heavily shorted/ manipulation.-90 million in cash / MC currently 80 million.

-$15 dollar PT just announced / more coming.

This will be 5-10 times this price in the near future .Just buy more when the callback comes!

GRTX has a birght future!